[go: up one dir, main page]

DK1899462T3 - Stabile vandige systemer omfattende proteiner - Google Patents

Stabile vandige systemer omfattende proteiner

Info

Publication number
DK1899462T3
DK1899462T3 DK06764894.9T DK06764894T DK1899462T3 DK 1899462 T3 DK1899462 T3 DK 1899462T3 DK 06764894 T DK06764894 T DK 06764894T DK 1899462 T3 DK1899462 T3 DK 1899462T3
Authority
DK
Denmark
Prior art keywords
protein
ionisable groups
stabilising
proteins
aqueous systems
Prior art date
Application number
DK06764894.9T
Other languages
English (en)
Inventor
Jan Jezek
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1899462(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513653.6A external-priority patent/GB0513653D0/en
Priority claimed from GBGB0610140.6A external-priority patent/GB0610140D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Application granted granted Critical
Publication of DK1899462T3 publication Critical patent/DK1899462T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DK06764894.9T 2005-07-02 2006-07-03 Stabile vandige systemer omfattende proteiner DK1899462T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0513653.6A GB0513653D0 (en) 2005-07-02 2005-07-02 Protein stability
GBGB0610140.6A GB0610140D0 (en) 2006-05-22 2006-05-22 Protein stability
PCT/GB2006/002470 WO2007003936A1 (en) 2005-07-02 2006-07-03 Stable aqueous systems comprising proteins

Publications (1)

Publication Number Publication Date
DK1899462T3 true DK1899462T3 (da) 2011-06-06

Family

ID=36940697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06764894.9T DK1899462T3 (da) 2005-07-02 2006-07-03 Stabile vandige systemer omfattende proteiner

Country Status (8)

Country Link
US (1) US20090148406A1 (da)
EP (3) EP1899462B1 (da)
JP (1) JP5033798B2 (da)
AT (1) ATE501248T1 (da)
CA (1) CA2614006C (da)
DE (1) DE602006020568D1 (da)
DK (1) DK1899462T3 (da)
WO (1) WO2007003936A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610140D0 (en) 2006-05-22 2006-06-28 Insense Ltd Protein stability
GB2435510A (en) * 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US20090136538A1 (en) * 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
JP5273438B2 (ja) * 2007-11-22 2013-08-28 国立大学法人東京農工大学 ペプチド付加生体分子の溶解度計算方法、及びそれを用いたペプチドタグの設計方法と封入体形成防止方法
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AR069989A1 (es) 2007-12-28 2010-03-03 Baxter Int Formulaciones de vwf recombinantes
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
WO2009133408A2 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
NZ592704A (en) 2008-10-21 2013-02-22 Baxter Int Lyophilized recombinant von willebrand factor (rVWF) formulation comprising buffering agents, amino acids, stabilising agents and surfactants
CA2742791A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
SG10201401995UA (en) * 2009-05-04 2014-08-28 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2726230A1 (en) * 2009-07-16 2010-08-19 Arecor Limited The stabilisation of proteins
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
ES2765418T3 (es) 2010-03-01 2020-06-09 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP6294075B2 (ja) 2010-05-28 2018-03-14 ノヴォ ノルディスク アー/エス 抗体及び防腐剤を含む安定した多用量組成物
LT2637690T (lt) 2010-11-11 2016-10-25 Abbvie Biotechnology Ltd Didelės koncentracijos anti-tnfalfa antikūno skystos kompozicijos
GB201113880D0 (en) * 2011-08-12 2011-09-28 Archimed Llp Novel compositions
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014125237A1 (en) 2013-02-12 2014-08-21 Microarray Limited Novel biosensor
FR3014446B1 (fr) 2013-12-10 2017-05-26 Biomerieux Sa Stabilisation de la gdh en solution aqueuse
CN104480095A (zh) * 2014-11-27 2015-04-01 广西大学 一种酶活力稳定的液态木瓜蛋白酶制剂
WO2017007837A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilizaton of proteins
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
WO2017044366A1 (en) 2015-09-11 2017-03-16 Dow Global Technologies Llc Polyalkoxy fatty compound
EP3347031B8 (en) 2015-09-11 2021-04-28 Nutrition & Biosciences USA 1, LLC A composition comprising a protein and a polyalkoxy fatty compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051627A (en) 1960-08-18 1962-08-28 Armour Pharma Stabilized chymotrypsin solution
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
CA2062659A1 (en) * 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
IT1247946B (it) 1991-05-17 1995-01-05 Instrumentation Lab Srl Stabilizzazione in forma liquida dell'enzima urato ossidasi
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TR199901968T2 (xx) 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
WO2002013860A1 (en) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
JP2002125693A (ja) * 2000-10-19 2002-05-08 Toyobo Co Ltd 無細胞タンパク質合成用細胞抽出液組成物
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
EP1438581A1 (en) * 2001-08-30 2004-07-21 Board Of Regents, The University Of Texas System Ensemble-based analysis of the ph-dependence of stability of proteins
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003055512A1 (en) * 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
CA2471879C (en) * 2002-05-21 2014-02-25 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition containing ghrelin
MXPA05007182A (es) * 2002-12-31 2006-04-07 Altus Pharmaceuticals Inc Complejos de cristales de proteina y polimeros ionicos.
JP2007500243A (ja) * 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 成長ホルモンの増進された経粘膜送達のための組成物および方法
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation

Also Published As

Publication number Publication date
JP2008544977A (ja) 2008-12-11
WO2007003936A1 (en) 2007-01-11
JP5033798B2 (ja) 2012-09-26
EP1899462B1 (en) 2011-03-09
DE602006020568D1 (de) 2011-04-21
US20090148406A1 (en) 2009-06-11
CA2614006C (en) 2014-11-04
EP2264161A1 (en) 2010-12-22
EP2264162A1 (en) 2010-12-22
EP1899462A1 (en) 2008-03-19
ATE501248T1 (de) 2011-03-15
CA2614006A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
DK1899462T3 (da) Stabile vandige systemer omfattende proteiner
ATE275378T1 (de) Wässrige kosmetische gele
BRPI0410616A (pt) xampu condicionador
WO2005003296A3 (en) Albumin fusion proteins
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
DE59805901D1 (de) Flüssige enzymzubereitung und ihre verwendung
TNSN08064A1 (en) Albumin fusion proteins
DK1309634T3 (da) Vandoplöselige eller vandkvældbare, sulfogruppeholdige, associativt fortykkende copolymerer, fremgangsmåde til fremstilling af samme samt anvendelse deraf
CO6612227A2 (es) Formulaciones concentradas acuosas que contienen saflufenacilo y glifosato
DK1100344T3 (da) Chitosanholdige flydende præparater og fremgangsmåder til deres fremstilling og anvendelse
BRPI0317696B8 (pt) composição para branqueamento
GB2446992A (en) Pathogen-controlling products
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
MA26913A1 (fr) Derives de beta-amino acide nitrile.
ATE414711T1 (de) Polymerstabilisierte proteinasen
ATE461276T1 (de) Enzymstabilisierung
ATE319758T1 (de) Stabilisierte wässrige polyurethan-polyharnstoff dispersionen
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
TR200301248A2 (tr) Antibiyotik Aktiviteye Sahip Olan Farmasotik Kompozisyonlar.
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
UA87506C2 (ru) Применение электролита как стабилизатора ингибитора
FR2840313B1 (fr) Composition a base d'une peinture aqueuse, notamment d'une lasure ou d'un vernis, et d'une dispersion colloidale aqueuse de cerium
WO2003059323A3 (de) Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren ii
BRPI0409564A (pt) sistema estabilizador para polìmeros halogenados
DE50005906D1 (de) Wässrige kunststoff-dispersionen mit erhöhter stabilität